SCA
ABBV icon

Sage Capital Advisors’s AbbVie ABBV Stock Holding History

Sage Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9M Buy
23,456
+165
+0.7% +$35.5K 1.22% 29
2026
Q1 		$5.07M Buy
23,291
+35
+0.2% +$7.76K 1.17% 33
2025
Q4 		$5.31M Sell
23,256
-8
-0% -$1.82K 1.26% 27
2025
Q3 		$5.39M Buy
23,264
+204
+0.9% +$41.5K 1.28% 27
2025
Q2 		$4.28M Buy
23,060
+247
+1% +$45.9K 1.06% 32
2025
Q1 		$4.78M Buy
22,813
+197
+0.9% +$38.3K 1.25% 29
2024
Q4 		$4.02M Buy
22,616
+161
+0.7% +$29.6K 1.05% 35
2024
Q3 		$4.43M Buy
22,455
+3,212
+17% +$599K 1.16% 27
2024
Q2 		$3.3M Buy
19,243
+332
+2% +$55K 0.95% 37
2024
Q1 		$3.44M Buy
18,911
+49
+0.3% +$8.45K 1% 38
2023
Q4 		$2.92M Buy
18,862
+319
+2% +$46.5K 0.94% 37
2023
Q3 		$2.76M Buy
18,543
+469
+3% +$68.8K 1.01% 37
2023
Q2 		$2.44M Buy
18,074
+2,063
+13% +$303K 0.85% 41
2023
Q1 		$2.55M Buy
16,011
+283
+2% +$43.3K 0.97% 36
2022
Q4 		$2.54M Sell
15,728
-36
-0.2% -$5.52K 1.12% 31
2022
Q3 		$2.12M Sell
15,764
-890
-5% -$128K 1.08% 31
2022
Q2 		$2.55M Sell
16,654
-5
-0% -$764 1.22% 28
2022
Q1 		$2.92M Sell
16,659
-26,961
-62% -$3.92M 1.18% 30
2021
Q4 		$5.9M Buy
43,620
+2,682
+7% +$317K 2.24% 10
2021
Q3 		$4.42M Buy
40,938
+461
+1% +$52.7K 1.88% 20
2021
Q2 		$4.74M Buy
40,477
+2,890
+8% +$325K 1.93% 16
2021
Q1 		$4.07M Sell
37,587
-27
-0.1% -$2.89K 1.82% 21
2020
Q4 		$4.08M Buy
37,614
+67
+0.2% +$6.44K 2.01% 14
2020
Q3 		$3.29M Buy
37,547
+15,279
+69% +$1.44M 2.01% 13
2020
Q2 		$2.19M Buy
22,268
+4
+0% +$352 1.4% 24
2020
Q1 		$1.7M Buy
+22,264
New +$1.9M 1.39% 22
2018
Q3 		– Sell
-18,009
Closed -$1.67M – 88
2018
Q2 		$1.67M Buy
+18,009
New +$1.76M 1.17% 29

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Sage Capital Advisors's ABBV Position: Q2 2026 in Review

Sage Capital Advisors increased its AbbVie (ABBV) stake by 0.71% in Q2 2026, buying an estimated $35.5K and bringing the position to 23,456 shares worth $5.9M. The position accounts for 1.22% of the portfolio, ranked #29.

Sage Capital Advisors first reported a position in ABBV in Q2 2018 and has held it in 27 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Sage Capital Advisors held 23,456 shares of AbbVie worth $5.9M as of Q2 2026.
  • Sage Capital Advisors bought 165 AbbVie shares in Q2 2026, an estimated $35.5K.
  • AbbVie made up 1.22% of Sage Capital Advisors's portfolio in Q2 2026, its #29 holding.
  • Sage Capital Advisors first reported a position in AbbVie in Q2 2018 and has held it in 27 quarters since.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Sage Capital Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.